Search

Your search keyword '"Ferté C"' showing total 143 results

Search Constraints

Start Over You searched for: Author "Ferté C" Remove constraint Author: "Ferté C"
Sorry, I don't understand your search. ×
143 results on '"Ferté C"'

Search Results

3. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

5. LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

9. Congrès Targeted Anticancer Therapies — TAT 2015

14. 326 (PB106) - Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

15. EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

17. EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

19. Referendum Report Of Council

21. Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial

22. Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial

23. MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

24. A novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1

27. 182TiP - EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

31. MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)

33. Predictive and Prognostic Value of CT Based Radiomics Signature in Head and Neck Squamous Cell Carcinoma Patients Treated With Concurrent Chemoradiation Therapy or Bioradiation Therapy and Its Added Value to Human Papillomavirus Status

47. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.

Catalog

Books, media, physical & digital resources